- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsing-remitting multiple sclerosis (RRMS)
- Meeting Date: May 2025
- Public Summary Document (PSD) May 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) May 2025 PBAC Meeting - (Word)
Ublituximab – May 2025
Ublituximab: Solution concentrate for I.V. infusion 150 mg in 6 mL (25 mg per mL); Briumvi®
Last updated
9 May 2025